Clinical Trial Update: Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial sponsored by Celgene evaluating lisocabtagene maraleucel (JCAR017) in adults with aggressive B-cell non-Hodgkin lymphoma has completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2024-12-27